Skip to Main Content

Author Details

Michael Allg??uer
Institute of Pathology, Heidelberg University Hospital
1991
88
32
PMIDPaper TitleJournal TitlePublished Year
36635225First proficiency testing for NGS-based and combined NGS- and FISH-based detection of FGFR2 fusions in intrahepatic cholangiocarcinoma.J Pathol Clin Res2023
37864096Multicentric pilot study to standardize clinical whole exome sequencing (WES) for cancer patients.NPJ Precis Oncol2023
37586177Analysis of rare fusions in NSCLC: Genomic architecture and clinical implications.Lung Cancer2023
37460340Prognostic Impact of the Immune-Cell Infiltrate in N1-Positive Non-Small-Cell Lung Cancer.Clin Lung Cancer2023
37141769Spatial profiling of the microenvironment reveals low intratumoral heterogeneity and STK11-associated immune evasion in therapy-naïve lung adenocarcinomas.Lung Cancer2023
36738756Accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy compared with whole-breast irradiation with boost for early breast cancer: 10-year results of a GEC-ESTRO randomised, phase 3, non-inferiority trial.Lancet Oncol2023
34331337Assigning evidence to actionability: An introduction to variant interpretation in precision cancer medicine.Genes Chromosomes Cancer2022
35384413Homologous recombination deficiency is inversely correlated with microsatellite instability and identifies immunologically cold tumors in most cancer types.J Pathol Clin Res2022
35668118MCL1 as putative target in pancreatoblastoma.Virchows Arch2022
37013123Indurated erythema of abdominal skin: An unusual presentation of metastatic endometrial carcinoma-Case report with literature review.Skin Health Dis2022
36423362COGNITION: a prospective precision oncology trial for patients with early breast cancer at high risk following neoadjuvant chemotherapy.ESMO Open2022
35871236Genomic architecture of FGFR2 fusions in cholangiocarcinoma and its implication for molecular testing.Br J Cancer2022
35918329Comprehensive genomic and epigenomic analysis in cancer of unknown primary guides molecularly-informed therapies despite heterogeneity.Nat Commun2022
33631297Artificial intelligence and pathology: From principles to practice and future applications in histomorphology and molecular profiling.Semin Cancer Biol2022
35058282Histological and molecular plasticity of ALK-positive non-small-cell lung cancer under targeted therapy: a case report.Cold Spring Harb Mol Case Stud2022
34792531Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Patients With Locally Advanced Rectal Cancer: Long-term Results of the CAO/ARO/AIO-12 Randomized Clinical Trial.JAMA Oncol2022
34125345Deciphering the immunosuppressive tumor microenvironment in ALK- and EGFR-positive lung adenocarcinoma.Cancer Immunol Immunother2022
33188943Loss of RNF43 Function Contributes to Gastric Carcinogenesis by Impairing DNA Damage Response.Cell Mol Gastroenterol Hepatol2021
33686791KRAS/GNAS-testing by highly sensitive deep targeted next generation sequencing improves the endoscopic ultrasound-guided workup of suspected mucinous neoplasms of the pancreas.Genes Chromosomes Cancer2021
33520406A gene expression signature associated with B cells predicts benefit from immune checkpoint blockade in lung adenocarcinoma.Oncoimmunology2021
33898315<i>De Novo</i> Versus Secondary Metastatic <i>EGFR</i>-Mutated Non-Small-Cell Lung Cancer.Front Oncol2021
33667718Targeting rare and non-canonical driver variants in NSCLC - An uncharted clinical field.Lung Cancer2021
34487971The immune microenvironment in EGFR- and ERBB2-mutated lung adenocarcinoma.ESMO Open2021
34012783Conventional and semi-automatic histopathological analysis of tumor cell content for multigene sequencing of lung adenocarcinoma.Transl Lung Cancer Res2021
34090172Effect of timing, technique and molecular features on brain control with local therapies in oncogene-driven lung cancer.ESMO Open2021
34112699Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with Rare Cancers.Cancer Discov2021
31431371Estimation of the α/β ratio of non-small cell lung cancer treated with stereotactic body radiotherapy.Radiother Oncol2020
31970771Integrated clinicomolecular characterization identifies RAS activation and CDKN2A deletion as independent adverse prognostic factors in cancer of unknown primary.Int J Cancer2020
33250961Cancer-related microangiopathic hemolytic anemia in patients with advanced gastric cancer: A retrospective single-center analysis.World J Gastrointest Oncol2020
32188579Correlating Dose Variables with Local Tumor Control in Stereotactic Body Radiation Therapy for Early-Stage Non-Small Cell Lung Cancer: A Modeling Study on 1500 Individual Treatments.Int J Radiat Oncol Biol Phys2020
32212351Immuno-oncology gene expression profiling of formalin-fixed and paraffin-embedded clear cell renal cell carcinoma: Performance comparison of the NanoString nCounter technology with targeted RNA sequencing.Genes Chromosomes Cancer2020
32143116Quantifying potential confounders of panel-based tumor mutational burden (TMB) measurement.Lung Cancer2020
32156527Metastatic adult pancreatoblastoma: Multimodal treatment and molecular characterization of a very rare disease.Pancreatology2020
30380024Loss of endogenous RNF43 function enhances proliferation and tumour growth of intestinal and gastric cells.Carcinogenesis2019
30028355A Cell Line-based Immunohistochemical p53 Expression Pattern Control Panel.Int J Gynecol Pathol2019
30238975Size matters: Dissecting key parameters for panel-based tumor mutational burden analysis.Int J Cancer2019
30230086Next generation sequencing of the cellular and liquid fraction of pancreatic cyst fluid supports discrimination of IPMN from pseudocysts and reveals cases with multiple mutated driver clones: First findings from the prospective ZYSTEUS biomarker study.Genes Chromosomes Cancer2019
31268125Optimizing panel-based tumor mutational burden (TMB) measurement.Ann Oncol2019
31491926RNA-Based Detection of Gene Fusions in Formalin-Fixed and Paraffin-Embedded Solid Cancer Samples.Cancers (Basel)2019
31349062Spatial and Temporal Heterogeneity of Panel-Based Tumor Mutational Burden in Pulmonary Adenocarcinoma: Separating Biology From Technical Artifacts.J Thorac Oncol2019
31628526Antisense targeting of CD47 enhances human cytotoxic T-cell activity and increases survival of mice bearing B16 melanoma when combined with anti-CTLA4 and tumor irradiation.Cancer Immunol Immunother2019
31444607Morphomolecular analysis of the immune tumor microenvironment in human head and neck cancer.Cancer Immunol Immunother2019
30808323The impact of local control on overall survival after stereotactic body radiotherapy for liver and lung metastases from colorectal cancer: a combined analysis of 388 patients with 500 metastases.BMC Cancer2019
31010589Several genotypes, one phenotype: PIK3CA/AKT1 mutation-negative hidradenoma papilliferum show genetic lesions in other components of the signalling network.Pathology2019
31150315Randomized Phase II Trial of Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: CAO/ARO/AIO-12.J Clin Oncol2019
31008532Variant classification in precision oncology.Int J Cancer2019
31167928Lymphocyte-driven regional immunopathology in pneumonitis caused by impaired central immune tolerance.Sci Transl Med2019
30963573Comparative genetic profiling aids diagnosis and clinical decision making in challenging cases of CUP syndrome.Int J Cancer2019
30653256Combined targeted DNA and RNA sequencing of advanced NSCLC in routine molecular diagnostics: Analysis of the first 3,000 Heidelberg cases.Int J Cancer2019
30669647Detection of TP53 Mutations in Tissue or Liquid Rebiopsies at Progression Identifies ALK+ Lung Cancer Patients with Poor Survival.Cancers (Basel)2019
  • 1 - 50 of 88

Recommended Authors

Stefano Cavalieri
Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, University of Milan
Career Start Year 2016
Number of shared co-authors 0
Zhengming Chen
Weill Cornell Medicine and New York Presbyterian Hospital
Career Start Year 2013
Number of shared co-authors 1
Nazim Benzerdjeb
Institut de Pathologie Multisite
Career Start Year 2013
Number of shared co-authors 0
Mich??le Orain
Institut Universitaire de Cardiologie et de Pneumologie de Quebec, Universite Laval
Career Start Year 2013
Number of shared co-authors 0
Jyoti Malhotra
Rutgers Cancer Institute of New Jersey, Robert Wood Johnson Medical School
Career Start Year 2012
Number of shared co-authors 0
Chen Hu
Johns Hopkins University School of Medicine
Career Start Year 2009
Number of shared co-authors 0
Ashiq Masood
Indiana University Melvin and Bren Simon Comprehensive Cancer Center
Career Start Year 2008
Number of shared co-authors 1
Gabriele Zoppoli
University of Genoa and Ospedale Policlinico San Martino
Career Start Year 2008
Number of shared co-authors 1
Iacopo Petrini
University of Pisa
Career Start Year 2006
Number of shared co-authors 2
Bhumsuk Keam
Seoul National University Hospital
Career Start Year 2006
Number of shared co-authors 0
Aruz Mesci
Juravinski Cancer Centre
Career Start Year 2006
Number of shared co-authors 1
Nadeem Riaz
Memorial Sloan Kettering Cancer Center
Career Start Year 2004
Number of shared co-authors 2
Pavlos Msaouel
The University of Texas MD Anderson Cancer Center
Career Start Year 2004
Number of shared co-authors 2
Daniel S Higginson
Memorial Sloan Kettering Cancer Center
Career Start Year 2003
Number of shared co-authors 0
Nicola Fusco
IEO European Institute of Oncology IRCCS
Career Start Year 2002
Number of shared co-authors 0
Zhigang Zhang
Memorial Sloan Kettering Cancer Center
Career Start Year 2001
Number of shared co-authors 0
Pingfu Fu
Case Western Reserve University
Career Start Year 2000
Number of shared co-authors 1
David Neil Hayes
Center for Cancer Research, University of Tennessee Health Science Center
Career Start Year 1999
Number of shared co-authors 2
Martijn P Lolkema
Erasmus MC Cancer Institute
Career Start Year 1999
Number of shared co-authors 1
Thomas J George
UF Health Cancer Center
Career Start Year 1998
Number of shared co-authors 0
Patrick Micke
Uppsala University
Career Start Year 1997
Number of shared co-authors 0
Puneeth Iyengar
UT Southwestern Medical Center, Center for Human Nutrition
Career Start Year 1996
Number of shared co-authors 0
Jorge Nieva
Norris Comprehensive Cancer Center, University of Southern California
Career Start Year 1995
Number of shared co-authors 0
Stefan Sleijfer
Erasmus MC Cancer Institute, University Medical Center Rotterdam
Career Start Year 1994
Number of shared co-authors 0
Paul Mitchell
Olivia Newton-John Cancer Research Institute
Career Start Year 1993
Number of shared co-authors 0
Melania Pintilie
Princess Margaret Cancer Centre, University Health Network
Career Start Year 1993
Number of shared co-authors 0
Philippe Lambin
Maastricht University
Career Start Year 1992
Number of shared co-authors 0
Paul T Fanta
University of California San Diego Moores Cancer Center
Career Start Year 1992
Number of shared co-authors 0
Jose A Lopez-Martin
Hospital Universitario 12 de Octubre
Career Start Year 1988
Number of shared co-authors 0
Helen J Ross
Mayo Clinic
Career Start Year 1982
Number of shared co-authors 0

Collaborators

Albrecht Stenzinger
Institute of Pathology, University Hospital Heidelberg
Co-authored papers 37
Peter Schirmacher
Institute of Pathology, University Hospital Heidelberg
Co-authored papers 32
Jan Budczies
Institute of Pathology, University Hospital Heidelberg
Co-authored papers 26
Daniel Kazdal
Institut fur Pathologie, Universitatsklinikum Heidelberg
Co-authored papers 23
Martina Kirchner
Institute of Pathology, University Hospital Heidelberg
Co-authored papers 23
Olaf Neumann
Institute of Pathology, University Hospital Heidelberg
Co-authored papers 20
Anna-Lena Volckmar
Institut fur Pathologie, Universitatsklinikum Heidelberg
Co-authored papers 19
Volker Endris
Institute of Pathology, University Hospital Heidelberg
Co-authored papers 19
Stefan Fr??hling
German Cancer Research Center (DKFZ), National Center for Tumor Diseases (NCT)
Co-authored papers 18
Karin Dieckmann
Medical University of Vienna
Co-authored papers 8
Peter Horak
German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT)
Co-authored papers 6
Huriye Seker-Cin
Institute of Pathology, Heidelberg University Hospital
Co-authored papers 5
Sebastian Uhrig
National Center for Tumor Diseases (NCT), German Cancer Research Center (DKFZ)
Co-authored papers 5
Markus Ball
Institute of Pathology, Heidelberg University Hospital
Co-authored papers 4
Barbara Hutter
National Center for Tumor Diseases (NCT) Heidelberg
Co-authored papers 4
Ivo Buchhalter
German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK)
Co-authored papers 4
Benedikt Brors
German Cancer Research Center (DKFZ)
Co-authored papers 3
Martha Quezado
National Cancer Institute (NCI), National Institutes of Health (NIH)
Co-authored papers 3
Frederick Klauschen
Institute of Pathology, Ludwig-Maximilians-Universitat Munchen
Co-authored papers 3
Simon Kreutzfeldt
German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT)
Co-authored papers 3
Thomas Longerich
Institute of Pathology, University Hospital Heidelberg
Co-authored papers 3
Holger S??ltmann
German Cancer Research Center (DKFZ)
Co-authored papers 3
Theo Heller
National Institute of Diabetes and Digestive and Kidney Diseases
Co-authored papers 2
Udo Rudloff
Center for Cancer Research, National Cancer Institute
Co-authored papers 2
Hans-Stefan Hofmann
Co-authored papers 2
Michael Vieth
Institute of Pathology, Friedrich-Alexander-University Erlangen-Nuremberg
Co-authored papers 2
Nikolas von Bubnoff
University Hospital of Schleswig-Holstein
Co-authored papers 2
Emmanouil Fokas
Universityhospital Frankfurt
Co-authored papers 2
Marc Zapatka
Co-authored papers 2
Susanne Beck
Vrije Universiteit Brussel (VUB)
Co-authored papers 2
Release 1.2